EMA/176734/2024

European Medicines Agency decision

P/0165/2024

of 6 May 2024

on the acceptance of a modification of an agreed paediatric investigation plan for live, attenuated, dengue virus, serotype 1 (DENV1) / live, attenuated, chimeric dengue virus, serotype 2 (DENV2) / live, attenuated, dengue virus, serotype 3 (DENV3) / live, attenuated, dengue virus, serotype 4 (DENV4), (EMEA-002999-PIP01-21-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0165/2024

of 6 May 2024

on the acceptance of a modification of an agreed paediatric investigation plan for live, attenuated, dengue virus, serotype 1 (DENV1) / live, attenuated, chimeric dengue virus, serotype 2 (DENV2) / live, attenuated, dengue virus, serotype 3 (DENV3) / live, attenuated, dengue virus, serotype 4 (DENV4), (EMEA-002999-PIP01-21-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0521/2022 issued on 30 December 2022,

Having regard to the application submitted by MSD Europe Belgium SRL on 8 December 2023 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 22 March 2024, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for live, attenuated, dengue virus, serotype 1 (DENV1) / live, attenuated, chimeric dengue virus, serotype 2 (DENV2) / live, attenuated, dengue virus, serotype 3 (DENV3) / live, attenuated, dengue virus, serotype 4 (DENV4), powder and solvent for solution for injection, subcutaneous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to MSD Europe Belgium SRL, Boulevard du Souverain 25, 1170 – Brussels, Belgium.

EMA/PDCO/11044/2024
Amsterdam, 22 March 2024

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-002999-PIP01-21-M01

Scope of the application

Active substance(s):

Live, attenuated, dengue virus, serotype 1 (DENV1) /

Live, attenuated, chimeric dengue virus, serotype 2 (DENV2) /

Live, attenuated, dengue virus, serotype 3 (DENV3) /

Live, attenuated, dengue virus, serotype 4 (DENV4)

Invented name and authorisation status:

See Annex II

Condition(s):

Prevention of dengue disease

Pharmaceutical form(s):

Powder and solvent for solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

MSD Europe Belgium SRL

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Merck Sharp & Dohme (Europe), Inc. submitted to the European Medicines Agency on 8 December 2023 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0521/2022 issued on 30 December 2022.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 22 January 2024.

On 1 February 2024 Merck Sharp & Dohme (Europe), Inc. requested to transfer the paediatric investigation plan to MSD Europe Belgium SRL.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Prevention of dengue disease

The waiver applies to:

- the paediatric population from birth to less than 2 months of age;
- powder and solvent for solution for injection; subcutaneous use;
- on the grounds that the specific medicinal product is likely to be ineffective.

2. Paediatric investigation plan

2.1. Condition:

Prevention of dengue disease

2.1.1. Indication(s) targeted by the PIP

Prevention of dengue disease

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 months of age to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder and solvent for solution for injection

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable
Non-clinical studies	Not applicable
Clinical studies	**Study 1 (DEN-03-IB)** Randomised, multicentre, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single dose of the Dengue 1,2,3,4 (live attenuated) vaccine produced by the Butantan Institute (Butantan-DV Dengue vaccine) in children from 2 years to less than 18 years of age for the prevention of dengue disease. **Study 2 (CLI-PED 2-17YO)** Randomised, double-blind, placebo-controlled safety and immunogenicity study of a single dose of live, attenuated, dengue virus, serotype 1 (DENV1) / live, attenuated, chimeric dengue virus, serotype 2 (DENV2) / live, attenuated, dengue virus, serotype 3

	(DENV3) / live, attenuated, dengue virus, serotype 4 (DENV4) (V181) in children from 2 years to less than 18 years of age for the prevention of dengue disease. **Study 3 (CLI-PED 2-23MO)** Randomised, double-blind, placebo-controlled safety and immunogenicity study of a single dose of live, attenuated, dengue virus, serotype 1 (DENV1) / live, attenuated, chimeric dengue virus, serotype 2 (DENV2) / live, attenuated, dengue virus, serotype 3 (DENV3) / live, attenuated, dengue virus, serotype 4 (DENV4) (V181) in children from 2 months of age to 23 months of age in endemic countries, for the prevention of dengue disease. **Study 4 (CLI Concom MMR Pent)** Randomised, double-blind, placebo controlled, cross-over safety and immunogenicity study in endemic countries of a single dose of live, attenuated, dengue virus, serotype 1 (DENV1) / live, attenuated, chimeric dengue virus, serotype 2 (DENV2) / live, attenuated, dengue virus, serotype 3 (DENV3) / live, attenuated, dengue virus, serotype 4 (DENV4) (V181) in children from 12 months of age to 15 months of age at enrolment, for the prevention of dengue disease. **Study 5 (CLI Concom YF)** Randomized, double-blind, placebo controlled, cross-over safety and immunogenicity study in endemic countries of a single dose of live, attenuated, dengue virus, serotype 1 (DENV1) / live, attenuated, chimeric dengue virus, serotype 2 (DENV2) / live, attenuated, dengue virus, serotype 3 (DENV3) / live, attenuated, dengue virus, serotype 4 (DENV4) (V181) in children from 12 months of age to 18 months of age at enrolment, for the prevention of dengue disease.
Modelling and simulation studies	Not applicable
Other studies	Not applicable
Extrapolation plan	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By February 2030
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.